BACKGROUND: Cholecystectomy remains the gold standard treatment of cholecystitis. Endoscopic treatment of cholecystitis includes transpapillary gallbladder drainage. Recently, endoscopic ultrasound-guided transmural drainage of the gallbladder (EUS-GBD) has been reported. This study reports the cumulative experience of an international group performing EUS-GBD. METHODS: Cases of EUS-GBD from January 2012 to November 2013 from 3 tertiary-care institutions were captured in a registry. Patient demographics, disease characteristics, procedural and clinical outcomes were recorded. RESULTS: 35 patients (15 malignant, 20 benign) were included. Median age was 81 years (SD=13.76 years), sixteen (46%) were males. Median follow-up was 91.5 days (SD=157 days). Transmural access was obtained from the stomach (n=17) or duodenum (n=18). Stents placed included plastic (n=6), metal (n=20), or combination (n=7). Technical success was achieved in 91.4% (n=32). Immediate adverse events (14%) included: bleeding, stent migration, cholecystitis and hemoperitoneum. Delayed adverse events (11%) included abscess formation and recurrence of cholecystitis. Long-term clinical success rate was 89%. Stent type and puncture site were not associated with immediate (p=0.88, p=0.62), or long-term (p=0.47, p=0.27) success. CONCLUSIONS: EUS-GBD appears to be feasible, safe, and effective. Prospective studies are needed to confirm these findings and identify the best technique to use. CLINICAL TRIAL REGISTRATION: NCT01522573.
BACKGROUND: Cholecystectomy remains the gold standard treatment of cholecystitis. Endoscopic treatment of cholecystitis includes transpapillary gallbladder drainage. Recently, endoscopic ultrasound-guided transmural drainage of the gallbladder (EUS-GBD) has been reported. This study reports the cumulative experience of an international group performing EUS-GBD. METHODS: Cases of EUS-GBD from January 2012 to November 2013 from 3 tertiary-care institutions were captured in a registry. Patient demographics, disease characteristics, procedural and clinical outcomes were recorded. RESULTS: 35 patients (15 malignant, 20 benign) were included. Median age was 81 years (SD=13.76 years), sixteen (46%) were males. Median follow-up was 91.5 days (SD=157 days). Transmural access was obtained from the stomach (n=17) or duodenum (n=18). Stents placed included plastic (n=6), metal (n=20), or combination (n=7). Technical success was achieved in 91.4% (n=32). Immediate adverse events (14%) included: bleeding, stent migration, cholecystitis and hemoperitoneum. Delayed adverse events (11%) included abscess formation and recurrence of cholecystitis. Long-term clinical success rate was 89%. Stent type and puncture site were not associated with immediate (p=0.88, p=0.62), or long-term (p=0.47, p=0.27) success. CONCLUSIONS: EUS-GBD appears to be feasible, safe, and effective. Prospective studies are needed to confirm these findings and identify the best technique to use. CLINICAL TRIAL REGISTRATION: NCT01522573.
Authors: Thomas R McCarty; Kelly E Hathorn; Ahmad Najdat Bazarbashi; Kunal Jajoo; Marvin Ryou; Christopher C Thompson Journal: Surg Endosc Date: 2021-07-06 Impact factor: 4.584
Authors: Raúl Torres Yuste; Francisco Javier García-Alonso; Ramón Sánchez-Ocana; Marta Cimavilla; Irene Peñas Herrero; Ana Yaiza Carbajo; Marina De Benito Sanz; Carlos De la Serna Higuera; Manuel Pérez-Miranda Journal: Ann Gastroenterol Date: 2019-06-20
Authors: Ali Siddiqui; Rastislav Kunda; Amy Tyberg; Mustafa A Arain; Arish Noor; Tayebah Mumtaz; Usama Iqbal; David E Loren; Thomas E Kowalski; Douglas G Adler; Monica Saumoy; Monica Gaidhane; Shawn Mallery; Eric M Christiansen; Jose Nieto; Michel Kahaleh Journal: Surg Endosc Date: 2018-09-12 Impact factor: 4.584
Authors: Seung Young Seo; Chang Hun Lee; In Hee Kim; Sang Wook Kim; Seung Ok Lee; Soo Teik Lee; Seong-Hun Kim Journal: Medicine (Baltimore) Date: 2020-07-02 Impact factor: 1.817